Publication Date:
2013-03-27
Description:
Nature Reviews Nephrology 9, 189 (2013). doi:10.1038/nrneph.2013.37 Authors: Rolf N. Barth & Jonathan S. Bromberg A new study by Lo et al. presents a novel immunosuppressive combination in a clinically relevant primate model of renal allografting. Using belatacept, a fusion protein that inhibits CD28–CD80/CD86 co-stimulation, plus the mammalian target of rapamycin inhibitor sirolimus, they were able to achieve rejection-free allograft survival without the induction of memory T cells or alloantibody.
Topics:
Medicine
Permalink